Clinical trial NCT04427787 - References

Neuroendocrine Tumors — A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

Citation(s)

•   Azar R, Najib S, Lahlou H, Susini C, Pyronnet S
  Phosphatidylinositol 3-kinase-dependent transcriptional silencing of the translational repressor 4E-BP1. Cell Mol Life Sci. 2008 Oct;65(19):3110-7. doi: 10.1007/s00018-008-8418-2.
•   Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlácková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators
  Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N
•   Chalabi M, Duluc C, Caron P, Vezzosi D, Guillermet-Guibert J, Pyronnet S, Bousquet C
  Somatostatin analogs: does pharmacology impact antitumor efficacy? Trends Endocrinol Metab. 2014 Mar;25(3):115-27. doi: 10.1016/j.tem.2013.11.003. Epub 2014 Jan 7. Revie
•   Krantic S, Goddard I, Saveanu A, Giannetti N, Fombonne J, Cardoso A, Jaquet P, Enjalbert A
  Novel modalities of somatostatin actions. Eur J Endocrinol. 2004 Dec;151(6):643-55. Review.
•   Pola S, Cattaneo MG, Vicentini LM
  Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity. J Biol Chem. 2003 Oct 17;278(42):40601-6. Epub 2003 Aug 5.
•   Rai U, Thrimawithana TR, Valery C, Young SA
  Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Pharmacol Ther. 2015 Aug;152:98-110. doi: 10.1016/j.pharmthera.2015.05.007. Epub 2015 May 5. Review.
•   Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P
  Sunitinib malate for the treatment
•   Susini C, Buscail L
  Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006 Dec;17(12):1733-42. Epub 2006 Jun 26. Review.

A Phase II Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in Gastroenteropancreatic (GEP) and Thoracic Neuroendocrine Tumor (NET): The LOLA Trial

Details for clinical trial NCT04427787